Development of Biomarkers or Composite Biomarkers for Neurological and Neuromuscular Disorders (R61/R33 - Clinical Trial Optional)
Department of Health and Human Services
The overarching purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and/or early evaluation of strong candidate biomarkers and biomarker signatures that can be used as tools to facilitate the clinical development of neurotherapeutics and their use in clinical practice. Specifically, the focus of this FOA is on the identification and initial biological, analytical and clinical evaluation of biomarkers and biomarker signatures for neurological and neuromuscular disorders. Although research supported by this FOA can include animal studies, it must also include preliminary human evaluation using carefully standardized human samples or datasets. The goal of this ini
Funding
Award size
Not specified
Type
Grant
Dates
Deadline
Later
Posted
10/28/2024
Closes
2028-01-07
Eligibility
Eligibility
Native American tribal governments (Federally recognized)For profit organizations other than small businessesCounty governmentsState governmentsNonprofits having a 501(c)(3) status with the IRS, other than institutions of higher educationPublic housing authorities/Indian housing authoritiesNonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher educationOthers (see text field entitled "Additional Information on Eligibility" for clarification)Independent school districtsNative American tribal organizations (other than Federally recognized tribal governments)City or township governmentsPrivate institutions of higher educationSmall businessesSpecial district governmentsPublic and State controlled institutions of higher education
Program
Funding area
Health - HL
Opportunity #
PAR-25-024
Source
Status
Open
Market
Government
Level
Federal
Source
Grants.gov